ALIM stock icon

Alimera Sciences
ALIM

$3.17
0.63%
 

About: Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.

Employees: 158

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

11% more funds holding

Funds holding: 35 [Q4 2023] → 39 (+4) [Q1 2024]

0.5% less ownership

Funds ownership: 92.01% [Q4 2023] → 91.51% (-0.5%) [Q1 2024]

10% less capital invested

Capital invested by funds: $208M [Q4 2023] → $187M (-$21.5M) [Q1 2024]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2023] → 4 (-1) [Q1 2024]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$6
89%
upside
Avg. target
$7.33
131%
upside
High target
$10
215%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
89%upside
$6
Buy
Reiterated
16 May 2024
Maxim Group
Naz Rahman
215%upside
$10
Buy
Initiated
25 Mar 2024
HC Wainwright & Co.
Yi Chen
89%upside
$6
Buy
Maintained
8 Mar 2024

Financial journalist opinion